Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew D. J. Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys, Caroline Thomas, Roberto Luksch, Ruth Ladenstein, Riccardo Haupt, Alberto Garaventa,
Cancer Res Treat. 2018;50(1):148-155.   Published online 2017 Mar 21     DOI: https://doi.org/10.4143/crt.2016.511
Citations to this article as recorded by Crossref logo
Molecular mechanisms and therapeutic targets in neuroblastoma
John Inge Johnsen, Cecilia Dyberg, Susanne Fransson, Malin Wickström
Pharmacological Research.2018; 131: 164.     CrossRef
Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias
OncoImmunology.2018; 7(9): e1468953.     CrossRef
Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
Joshua Felgenhauer, Laura Tomino, Julia Selich-Anderson, Emily Bopp, Nilay Shah
Neoplasia.2018; 20(10): 965.     CrossRef
Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
Loredana Amoroso, Riccardo Haupt, Alberto Garaventa, Mirco Ponzoni
Expert Opinion on Investigational Drugs.2017; 26(11): 1281.     CrossRef